131 related articles for article (PubMed ID: 36858004)
1. Brain imaging in lung cancer staging: A real-world, multi-centre study of prevalence of brain metastases, impact on treatment and re-modelling of the NICE health economic analysis.
Brockelsby C; Maconachie R; Navani N; Prendecki R; Randles V; King J; Dildar B; Lee X; Nagarajan T; Rice M; Al-Najjar H; Atkins A; Sundar R; Brown L; Sharma S; O'Dowd E; Crisp E; Tufail M; Vella C; Grundy S; Evison M
Lung Cancer; 2023 Apr; 178():145-150. PubMed ID: 36858004
[TBL] [Abstract][Full Text] [Related]
2. Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis.
Rice SR; Molitoris JK; Vyfhuis MAL; Edelman MJ; Burrows WM; Feliciano J; Nichols EM; Suntharalingam M; Donahue J; Carr SR; Friedberg J; Badiyan S; Simone CB; Feigenberg SJ; Mohindra P
Clin Lung Cancer; 2019 Jan; 20(1):e107-e114. PubMed ID: 30337268
[TBL] [Abstract][Full Text] [Related]
3. Screening for brain metastases in patients with stage III non-small cell lung cancer: Is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain?
Hendriks LE; Bootsma GP; de Ruysscher DK; Scheppers NA; Hofman PA; Brans BT; Dingemans AM
Lung Cancer; 2013 Jun; 80(3):293-7. PubMed ID: 23518381
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
7. Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.
Schoenmaekers J; Hofman P; Bootsma G; Westenend M; de Booij M; Schreurs W; Houben R; De Ruysscher D; Dingemans AM; Hendriks LEL
Eur J Cancer; 2019 Jul; 115():88-96. PubMed ID: 31129385
[TBL] [Abstract][Full Text] [Related]
8. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2020 Aug; 146():112-119. PubMed ID: 32526601
[TBL] [Abstract][Full Text] [Related]
9. Routine preoperative brain CT in resectable non-small cell lung cancer - Ten years experience from a tertiary UK thoracic center.
Matys T; Drury R; David S; Rassl DM; Qian W; Rintoul RC; Screaton NJ
Lung Cancer; 2018 Aug; 122():195-199. PubMed ID: 30032831
[TBL] [Abstract][Full Text] [Related]
10. Non-small cell lung cancer brain metastasis screening in the era of positron emission tomography-CT staging: Current practice and outcomes.
Diaz ME; Debowski M; Hukins C; Fielding D; Fong KM; Bettington CS
J Med Imaging Radiat Oncol; 2018 Jun; 62(3):383-388. PubMed ID: 29745036
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Non-Small Cell Lung Cancer.
Kim M; Suh CH; Lee SM; Kim HC; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
Radiology; 2020 Nov; 297(2):419-427. PubMed ID: 32840470
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
13. Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.
Erb CT; Su KW; Soulos PR; Tanoue LT; Gross CP
Lung Cancer; 2016 Sep; 99():200-7. PubMed ID: 27565940
[TBL] [Abstract][Full Text] [Related]
14. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
Dunlop W; van Keep M; Elroy P; Perez ID; Ouwens MJNM; Sarbajna T; Zhang Y; Greystoke A
Pharmacoecon Open; 2022 Mar; 6(2):241-252. PubMed ID: 34532842
[TBL] [Abstract][Full Text] [Related]
16. Brain Imaging for Staging of Patients With Clinical Stage IA Non-small Cell Lung Cancer in the National Lung Screening Trial: Adherence With Recommendations From the Choosing Wisely Campaign.
Balekian AA; Fisher JM; Gould MK
Chest; 2016 Apr; 149(4):943-50. PubMed ID: 26356134
[TBL] [Abstract][Full Text] [Related]
17. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.
Schneider BJ; Ismaila N; Aerts J; Chiles C; Daly ME; Detterbeck FC; Hearn JWD; Katz SI; Leighl NB; Levy B; Meyers B; Murgu S; Nekhlyudov L; Santos ES; Singh N; Tashbar J; Yankelevitz D; Altorki N
J Clin Oncol; 2020 Mar; 38(7):753-766. PubMed ID: 31829901
[TBL] [Abstract][Full Text] [Related]
18. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness and cost-effectiveness of endobronchial and endoscopic ultrasound relative to surgical staging in potentially resectable lung cancer: results from the ASTER randomised controlled trial.
Sharples LD; Jackson C; Wheaton E; Griffith G; Annema JT; Dooms C; Tournoy KG; Deschepper E; Hughes V; Magee L; Buxton M; Rintoul RC
Health Technol Assess; 2012; 16(18):1-75, iii-iv. PubMed ID: 22472180
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe.
Zemanova M; Jakopovic M; Stanic K; Łazar-Poniatowska M; Vrankar M; Rusu P; Ciuleanu T; Radosavljevic D; Bogos K; Nawrocki S
Radiol Oncol; 2020 Oct; 54(4):447-454. PubMed ID: 33048837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
